Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Fennec launches European Named Patient Program for sodium thiosulfate

May 31, 2017

Selecta initiates phase I trial of nicotine vaccine candidate SELA-070

May 15, 2017

Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study

May 9, 2017

Cleveland BioLabs updates entolimod progress

April 18, 2017

Battelle and Nanotherapeutics form alliance on medical countermeasures

April 6, 2017

SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA

April 3, 2017

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

March 28, 2017

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

March 2, 2017

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

Feb. 23, 2017

FDA issues complete response letter for Amphastar's intranasal naloxone

Feb. 23, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy
BioWorld
Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights,...